Streetbeat News

ARVN

Arvinas, Inc.

https://www.arvinas.com

Industry

Biotechnology

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

Open

25.01

Mkt cap

1.5B

Volume

656K

High

25.10

P/E Ratio

-4.69

52-wk high

53.08

Low

22.46

Div yield

N/A

52-wk low

20.28

Jefferies analyst Akash Tewari upgraded Arvinas (NASDAQ:ARVN) from Hold to Buy and increased the price target from $32 to $40, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:08 pm

Arvinas, Inc. (ARVN) stock price increased following the announcement of positive interim data from a Phase 1b trial of Vepdegestrant in combination with Palbociclib, conducted in partnership with Pfizer.

Portfolio Pulse from Benzinga Newsdesk

December 06, 2023 | 4:06 pm

THOR Industries reported better-than-expected quarterly earnings of 99 cents per share against estimates of 98 cents, with sales of $2.50 billion versus $2.498 billion expected, sending its shares up 6.5%. Other stocks also moved higher, with significant gains following positive earnings, clinical study results, strategic moves, and financial updates.

Portfolio Pulse from Lisa Levin

December 06, 2023 | 3:48 pm

Arvinas and Pfizer are set to present updated clinical trial data for Vepdegestrant (ARV-471), a novel oral estrogen receptor degrader, at the 2023 San Antonio Breast Cancer Symposium. The drug is being studied for the treatment of ER+/HER2- breast cancer.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 10:07 pm

Arvinas Inc (NASDAQ:ARVN) shares rose 11.2% after announcing a $350 million private placement of common stock and pre-funded warrants. The funds will support clinical programs, preclinical pipeline, and general operations. The placement, co-led by EcoR1 Capital and RTW Investments, LP, is set to close on November 28. BofA Securities, Inc. and Goldman Sachs & Co. LLC were the joint lead placement agents.

Portfolio Pulse from Henry Khederian

November 27, 2023 | 3:47 pm

Arvinas, Inc. stock (ARVN) is trading higher following the announcement of a successful $350 million private placement, which was oversubscribed.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 3:17 pm

Arvinas, Inc. has announced an oversubscribed private placement worth $350 million. The company will sell nearly 13 million shares at $21.36 each and pre-funded warrants for an additional 3.4 million shares at $21.359 each. This capital raise indicates investor confidence and may be used to fund Arvinas' operations and growth initiatives.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:05 pm

Guggenheim analyst Michael Schmitz has upgraded Arvinas (NASDAQ:ARVN) from Neutral to Buy and set a price target of $40 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 11:49 am

Azenta, Inc. reported Q4 earnings of 13 cents per share, surpassing estimates of 2 cents, with sales of $172.36 million against expectations of $163.9 million, causing its shares to rise 15.1%. Other stocks also moved higher, with Talis Biomedical exploring strategic alternatives and announcing a cost reduction plan, and various companies like Paysafe Limited and Sally Beauty Holdings reporting upbeat earnings. Adaptive Biotechnologies was maintained with an Overweight rating by Piper Sandler, and Agiliti, Inc. was upgraded by UBS. Zillow Group entered a new agreement with PHH Mortgage, and Snap Inc. saw gains following a deal to run Amazon shopping ads.

Portfolio Pulse from Lisa Levin

November 14, 2023 | 3:39 pm

Arvinas (NASDAQ:ARVN) has received 9 analyst ratings in the last quarter, with 4 bullish, 4 somewhat bullish, and 1 indifferent. No bearish ratings were reported. The average 12-month price target for Arvinas is $45.56, with a high of $72.00 and a low of $20.00. This average has decreased by 12.15% from the previous average price target of $51.86. Analysts rate stocks typically once per quarter and may provide earnings, revenue, and growth estimates.

Portfolio Pulse from Benzinga Insights

November 13, 2023 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.